Eli Lilly has received FDA approval and expanded labelling for its Lyumjev rapid-acting insulin. Lyumjev is a novel formulation of insulin lispro for speeding up
The FDA has approved an extended-release version of the GLP-1 drug exenatide for older children and teenagers with Type 2 diabetes, Andrew Briskin report for
On 14 July Eli Lilly and Company announced the acquisition of Protomer Technologies (“Protomer”), a private biotech company. Protomer’s proprietary peptide- and protein-engineering platform is
Spirit Pharmacy, the UK’s only home delivery pharmacy offering tailored services for people living with diabetes, has launched its free Live Well With Diabetes package.
A new emergency glucagon treatment is to become available in the United States from June 2021. Zegalogue – also known as dasiglucagon injection – was recently
A landmark trial shows that an immunotherapy drug can delay Type 1 diabetes by an average of three years. Previously, in 2019, researchers from the
JDRF and Diabetes UK issued a joint statement to the diabetes community on UK supplies of insulin in the build-up to the UK’s trade negotiations
A once-weekly basal insulin is in development to help treat Type 2 diabetes. Researchers suggest that reducing the frequency of basal insulin injections might help
A medication to treat Type 2 diabetes has significantly reduced blood sugar and body weight in participants of a late-phase clinical trial. Eli Lilly’s Tirzepatide is in
The FDA has approved Lilly’s Lyumjev rapid-acting mealtime insulin to reduce high blood sugar after meals and keep blood glucose levels in-range. This approval offers
